Metropolitan Life Insurance CO Cure Vac N.V. Transaction History
Metropolitan Life Insurance CO
- $252 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding CVAC
# of Institutions
86Shares Held
10.5MCall Options Held
75.5KPut Options Held
33.5K-
Black Rock Inc. New York, NY2.25MShares$7.41 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$5.42 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.57MShares$5.16 Million10.6% of portfolio
-
Ubs Group Ag577KShares$1.9 Million0.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL500KShares$1.65 Million0.01% of portfolio
About CureVac N.V.
- Ticker CVAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,467,008
- Market Cap $617M
- Description
- CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...